Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329122 | 1.00 | CMA1 (0.43) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605507 | 0.97 | CMA1 (0.40) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL16329060 | 0.97 | CMA1 (0.40) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL16329066 | 0.92 | CTSS (0.43) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605529 | 0.92 | CTSS (0.43) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605523 | 0.91 | CTSS (0.44) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605487 | 0.91 | CTSS (0.44) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605473 | 0.89 | CTSS (0.42) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605456 | 0.89 | CTSS (0.42) | CMA1CTSSCTSKCTSVCTSL | |
| SCHEMBL12605505 | 0.89 | F2 (0.43) | CMA1ELANEF2PRSS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CMA1 114/4885CTSS 112/4885CTSK 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.